Success Metrics

Completion Rate

0%(0/4)

Active Trials

0(0%)

Terminated

4(80%)

Phase Distribution

Ph phase_3

40%

Ph phase_1

20%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

2(40.0%)

Phase 3Large-scale testing

2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 5 finished

Non-Completion Rate

100.0%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Terminated(5)

Detailed Status

Terminated4

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (20.0%)

Phase 22 (40.0%)

Phase 32 (40.0%)

Trials by Status

terminated480%

withdrawn120%

Recent Activity

0 active trials

Showing 5 of 5

withdrawnphase_2

Melflufen for Elderly Patients With Relapsed Myeloma

NCT06682637

terminatedphase_3

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

NCT03151811

terminatedphase_3

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

NCT04649060

terminatedphase_2

PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function

NCT03639610

terminatedphase_1

Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients

NCT01897714

Clinical Trials (5)

Showing 5 of 5 trials

NCT06682637Phase 2

Melflufen for Elderly Patients With Relapsed Myeloma

Withdrawn

NCT03151811Phase 3

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

Terminated

NCT04649060Phase 3

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

Terminated

NCT03639610Phase 2

PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function

Terminated

NCT01897714Phase 1

Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients

Terminated

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5